TV commercials for prescription drugs: A discourse analytic perspective

Research in Social and Administrative Pharmacy

Volumn 1, Issue 2, 2005, Pages 158-184

  Glinert, Lewis H ^a  

^a DARTMOUTH COLLEGE   (United States)

Author keywords

Benefit risk information; Discourse analysis; Esomeprazole magnesium; Prescription drugs

Indexed keywords

DRUG;

ADVERTIZING; ARTICLE; HUMAN; INTERPERSONAL COMMUNICATION; LANGUAGE; LINGUISTICS; TELEVISION;

ADVERTISING; ADVERTISING AS TOPIC; COMMUNICATION; HUMANS; LANGUAGE; LINGUISTICS; PHARMACEUTICAL PREPARATIONS; TELEVISION;

EID: 33745946436     PISSN: 15517411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sapharm.2005.03.003     Document Type: Article

References (87)

1. Nelson P. Advertising as information. J Polit Econ 82 (1974) 729-753
2. Comanor W.S., and Wilson T.A. The effect of advertising on competition: a survey. J Econ Lit 17 (1979) 473-476
3. Cook G. The Discourse of Advertising. 2nd ed. (2001), Routledge, New York
4. Geis M. The Language of Television Advertising (1982), Academic Press, New York
5. Wason P.C., and Johnson-Laird P. Psychology of Reasoning: Form and Content (1972), Harvard University Press, Cambridge
6. Grafton-Small R., and Linstead S. Advertisements as artifacts: everyday understanding and the creative consumer. Int J Advert 8 (1989) 205-218
7. Sperber D., and Wilson D. Relevance: Communication and Cognition (1986), Harvard University Press, Cambridge, Mass
8. Brown G., and Yule G. Discourse Analysis (1983), Cambridge University Press, Cambridge
9. Proctor S., Proctor T., and Papasolomon-Doukakis I. A post-modern perspective on advertisements and their analysis. J Mark Commun 8 (2002) 31-44
10. In: Goodman S., and Graddol D. (Eds). Redesigning English: New Texts, New Identities (1996), Routledge, New York
11. Terzian T.V. Direct to consumer prescription drug advertising. Am J Law Med 25 (1999) 149-167
12. Ostrove N. Statement before the Subcommittee on Consumer Affairs, Foreign Commerce, and Tourism Senate Committee on Commerce, Science, and Transportation (July 24, 2001). Accessed 12.18.04
13. Federal Register: Notices. May 16, 2002; 67, No 95.
14. Ingram R.A. Some comments on direct-to-consumer advertising. J Pharm Mark Manage 7 (1992) 67-74
15. Peyrot M., Alperstein N.M., Van Doren D., and Poli L.G. Direct-to-consumer ads can influence behavior: advertising increases consumer knowledge and prescription drug requests. Mark Health Serv 18 (1998) 26-32
16. Holmer A.F. Direct-to-consumer prescription drug advertising builds bridges between patients and physicians. JAMA 281 (1999) 380-382
17. Bell R.A., Wilkes M.S., and Kravitz R.L. The educational value of consumer-targeted prescription drug print advertising. J Fam Pract 49 (2000) 1092-1098
18. Slaughter E., and Schumacher M. Prevention's International Survey on Wellness and Consumer Reactions to DTC Advertising of Rx Drugs (2000/2001), Rodale Press, Allentown, Pa
19. Moberg M.A., Wood J.W., and Dorfman H.L. Surfing the Net in shallow waters: product liability concerns and advertising on the Internet. Food Drug Law J 53 (1998) 213-224
20. Aikin KJ, Swasy JL, Braman AC. Patient and physician attitudes and behaviors associated with DTC promotion of prescription drugs-summary of FDA survey research results. Final report. FDA/Center for Drug Evaluation and Research. 2004.
21. Perri III M., Shinde S., and Banavali R. The past, present and future of direct-to-consumer prescription drug advertising. Clin Ther 21 (1999) 1798-1811
22. Farrell J.M. The ethical implications of direct-to-consumer pharmaceutical advertising. Philos Public Policy Q 23 (2003) 20-23
23. DDMAC untitled letter dated April 20, 1998 to Glaxo Wellcome concerning Zyban (bupropion HCl) sustained-release tablets. . Accessed 11.30.04.
24. DDMAC untitled letter dated March 20, 1998 to Alcon Laboratories concerning Patanol (olopatadine hydrochlorise opthalmic solution) 0.1%. . Accessed 11.30.04.
25. DDMAC untitled letter dated October 29, 2004 to Abbott Laboratories concerning Kaletra (lopinavir/ritonavir) capsules and oral suspension. . Accessed 12.14.04.
26. Baylor-Henry M., and Drezin N.A. Regulation of prescription drug promotion: direct-to-consumer advertising. Clin Ther 20 (1998) C86-C95
27. Scheineson M. Outline of FDA/FTC marketing rules. Paper presented at the DIA (Drug Information Association) "Marketing of Pharmaceuticals" meeting. New York; February 24-25, 2003.
28. ACP-ASIM position paper: direct to consumer advertising for prescription drugs. October 9, 1998.
29. AMA docket, December 1, 2003, Division of Dockets Management [HFA-305], Food and Drug Administration. . Accessed 12.10.04.
30. Coulter A. Evidence based patient information. BMJ 317 (1998) 225-226
31. Morris L., Ruffner M., and Klimberg R. Warning disclosures for prescription drugs. J Advert Res 25 (1987) 25-32
32. Morris L.A., Mazis M.B., and Brinberg D. Risk disclosures in televised prescription drug advertising to consumers. J Public Policy Market 8 (1989) 64-80
33. Kopp S.W., and Bang H.K. Benefit and risk information in prescription drug advertising: review of empirical studies and marketing implications. Health Mark Q 17 (2000) 39-56
34. Kaphingst K.A., and DeJong W. The educational potential of direct-to-consumer prescription drug advertising. Health Aff 23 (2004) 143-150
35. Glinert LH, Schommer J. Television advertisement format and the provision of risk information about prescription drug products. Res Soc Adm Pharm; 1:185-210.
36. Roth M. Patterns in direct-to-consumer prescription drug print advertising and their public policy implications. J Public Policy Mark 15 (1996) 63-75
37. Woloshin S., Schwartz L.M., Tremmel J., and Welch H.G. Direct-to-consumer advertisements for prescription drugs: what are Americans being sold?. Lancet 358 (2001) 1141-1146
38. Schwartz L., and Woloshin S. The case for letting information speak for itself. Eff Clin Pract 4 (2001) 76-79
39. FDA public meeting: direct-to-consumer promotion. Washington DC (September 22-23, 2003). Accessed 12.10.04
40. Kaphingst K.A. Examining the Educational Potential of Direct-to-consumer Prescription Drug Advertising (2002), Harvard School of Public Health, Boston
41. Kaphingst KA, DeJong W, Rudd RE, Daltroy LH. A content analysis of direct-to-consumer television prescription drug advertisements. J Health Commun. 2004; 515-528.
42. Sumpradit N., Ascione F.J., and Bagozzi R.P. A cross-media content analysis of motivational themes in direct-to-consumer prescription drug advertising. Clin Ther 26 (2004) 135-154
43. Brown G., and Yule G. Discourse Analysis (1983), Cambridge University Press, Cambridge
44. Jørgensen M.W., and Phillips L.J. Discourse Analysis as Theory and Method (2002), Sage, Thousand Oaks, Calif
45. Potter J. Discourse analysis as a way of analysing naturally occurring talk. In: Silverman D. (Ed). Qualitative Analysis: Issues of Theory and Method. 2nd ed. (2004), Sage, London 200-221
46. In: Wodak R., and Meyer M. (Eds). Methods of Critical Discourse Analysis (2001), Sage, London
47. Levinson S.C. Pragmatics (1983), Cambridge University Press, Cambridge
48. Hymes D.H. Foundations in Sociolinguistics: an Ethnographic Approach (1974), University of Pennsylvania Press, Philadelphia
49. In: Gumperz J.J. (Ed). Language and Social Identity (1982), Cambridge University Press, Cambridge
50. In: Tannen D. (Ed). Framing in Discourse (1993), Oxford University Press, Oxford
51. Silverman D. Harvey Sacks: Social Science and Conversation Analysis (1998), Oxford University Press, New York
52. Goffman I. Forms of Talk (1981), University of Pennsylvania Press, Philadelphia
53. Schiffrin D. "Speaking for another" in sociolinguistic interviews: alignment, identities and frames. In: Tannen D. (Ed). Framing in Discourse (1993), Oxford University Press, Oxford 231-263
54. Chafe W. Creativity in verbalization and its implications for the nature of stored knowledge. In: Freedle R. (Ed). Discourse Production and Comprehension (1977), Ablex Publishing Corp, Norwood, NJ 41-55
55. Tannen D. What's in a frame? Surface evidence for underlying expectations. In: Tannen D. (Ed). Framing in Discourse (1993), Oxford University Press, Oxford 14-56
56. Bakhtin M. The Dialogical Imagination (1981), University of Texas Press, Austin, Tex
57. Meinhof U. From the street to the screen: Breadline Britain and the semiotics of poverty. In: Meinhof U., and Richardson K. (Eds). Text, Discourse and Context: Representations of Poverty in Britain (1994), Longman, New York 67-92
58. Van Leeuwen T., and Kress G. Reading Images (1996), Routledge, London
59. Van Leeuwen T. Speech, Music, Sound (1999), Macmillan, London
60. McQuarrie E.F., and Mick D.G. Visual rhetoric in advertising: text-interpretive, experimental, and reader-response analyses. J Consum Res 26 (1999) 37-53
61. Stern B. Literary criticism and consumer research: overview and illustrative analysis. J Consum Res 16 (1989) 322-334
62. Goldman R. Reading Advertisements Socially (1992), Routledge, London
63. Phillips B.J., and McQuarrie E.F. Beyond visual metaphor: a new typology of visual rhetoric in advertising. Mark Theory 4 (2004) 113-136
64. Foucault M. The Archaeology of Knowledge (1972), Tavistock, London
65. Fairclough N. Discourse and Social Change (1992), Polity Press, Cambridge, Mass
66. Pennycook A. Incommensurable discourses. Appl Linguist 15/2 (1994) 112-138
67. Stubbs M. Text and Corpus Analysis (1996), Blackwell, Oxford
68. Strauss A., and Corbin J. Basics of Qualitative Research: Grounded Theory Procedures and Techniques (1998), Sage, Thousand Oaks, Calif
69. Bartlett D., and Payne S. Grounded theory-its basis, rationale and procedures. In: McKenzie G., Powell J., and Usher R. (Eds). Understanding Social Research: Perspectives on Methodology and Practice (1997), Falmer Press, London 173-195
70. Bennett A. Interruptions and the interpretation of conversation. Proceedings of the Fourth Annual Meeting of the Berkeley Linguistics Society. Berkeley; 1978:557-575.
71. Tannen D. Interpreting interruption in conversation. Papers from the 25th annual regional meeting of the Chicago Linguistics Society. Chicago; 1989:266-287.
72. Perkins M. Modal Expressions in English (1983), Ablex Publishing Corp, Norwood, NJ
73. Bybee J., and Fleischman S. Modality in grammar and discourse: an introductory essay. In: Bybee J., and Fleischman S. (Eds). Modality in Grammar and Discourse (1995), John Benjamins, Amsterdam 1-14
74. Nwogu K.N. Structure of science popularizations: a genre-analysis approach to the schema of popularized medical texts. Engl Special Purp 10 (1991) 111-124
75. Myers G.A. Textbooks and the sociology of scientific knowledge. Engl Special Purp 11 (1992) 3-18
76. Sweetser E. From Etymology to Pragmatics: Metaphorical and Cultural Aspects of Semantic Structure (1990), Cambridge University Press, Cambridge
77. Blum-Kulka S., and Olshtain E. Requests and apologies: a cross-cultural study of speech act realization patterns (CCSARP). Appl Linguist 5 (1984) 196-213
78. Schank R.C., and Abelson R.P. Scripts, Plans, Goals and Understanding (1977), Lawrence Erlbaum, Hillsdale, NJ
79. Noordman L.G.M., and Vonk W. Readers' knowledge and the control of inferences in reading. Language Cogn Process 7 (1992) 373-391
80. Searle J. Speech Acts (1969), Cambridge University Press, Cambridge
81. Grimshaw A. Code-switching or code-mixing: apparent anomalies in semi-formal registers. In: Slobin D., Gerhardt J., Kyratzis A., and Guo G. (Eds). Social Interaction, Social Context and Language: Studies Presented to Susan Ervin-Tripp (1996), Lawrence Erlbaum, Hillsdale, NJ 83-98
82. Brown S. Post-modern Marketing (1995), Routledge, London
83. Levi-Strauss C. The Savage Mind (1966), University of Chicago Press, Chicago
84. Day R. Cognitive accessibility of prescription drug information. Presentation to the FDA Public Meeting: Direct-to-consumer Promotion. Washington, DC; September 22-23, 2003.
85. Davis K. Power Under the Microscope (1988), Foris, Dordrecht
86. FDA. Guidance for Industry, Consumer-directed Broadcast Advertisements (1999), US Department of Health and Human Services, Food and Drug Administration, DDMAC
87. Ley P. Communicating With Patients (1998), Croom Helm, London